American Journal of Health-System Pharmacy最新文献_第10页

Incorporating project management into the profession of pharmacy. 将项目管理纳入药学专业。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2024-09-23 DOI: 10.1093/ajhp/zxae121

Lara K Ellinger, Sandeep Devabhakthuni, Becky S Linn, Keith D Posendek

引用次数: 0

Actions of the ASHP Board of Directors - Meeting of April 11-12, 2024. ASHP 董事会行动 - 2024 年 4 月 11-12 日会议。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2024-09-23 DOI: 10.1093/ajhp/zxae206

引用次数: 0

The role of the chief pharmacy officer in leading analytics strategy to support the enterprise. 首席药剂师在领导分析战略以支持企业方面的作用。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2024-09-23 DOI: 10.1093/ajhp/zxae064

David Aguero, Mary-Haston Vest, Jennifer Tryon

引用次数: 0

Ceftobiprole Medocaril Sodium. 头孢比普乐 Medocaril Sodium。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2024-09-23 DOI: 10.1093/ajhp/zxae178

引用次数: 0

Mavorixafor. Mavorixafor.

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2024-09-23 DOI: 10.1093/ajhp/zxae179

引用次数: 0

The impact of sugammadex dosing and administration practices on potential cost savings for pharmacy departments. 舒降之剂量和给药方法对药房部门潜在成本节约的影响。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2024-09-23 DOI: 10.1093/ajhp/zxae124

Dustin D Linn, Johnathan R Renew

{"title":"The impact of sugammadex dosing and administration practices on potential cost savings for pharmacy departments.","authors":"Dustin D Linn, Johnathan R Renew","doi":"10.1093/ajhp/zxae124","DOIUrl":"10.1093/ajhp/zxae124","url":null,"abstract":"Purpose: Neuromuscular blocking agents (NMBAs) are commonly used during surgery, and restoring neuromuscular function at the end of surgery is vital in preventing complications of residual paralysis. Recent guidelines from the American Society of Anesthesiology recommend using sugammadex over neostigmine; however, sugammadex is significantly more expensive than neostigmine and may increase drug expenditure for pharmacy departments. This review summarizes evidence evaluating sugammadex dose adjustments and the potential of these dose adjustments to lead to cost savings for pharmacy departments.Summary: We found evidence suggesting that the manufacturer-recommended sugammadex dose may not be needed in many patients and that dosing based on an adjusted body weight or based on depth of neuromuscular blockade may lead to lower sugammadex usage. Combining sugammadex with neostigmine could also decrease the dose of sugammadex required. We have highlighted the importance of objective neuromuscular monitoring to guide sugammadex dosing and evaluation for residual neuromuscular blockade. Cost savings for pharmacy departments may be realized by these alternative dosing strategies and/or vial-splitting practices.Conclusion: Implementing practices related to sugammadex vial splitting and dose adjustment based on body weight and depth of neuromuscular blockade shows potential benefits in terms of sugammadex cost savings.","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140896855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Price transparency at the point of prescribing with real-time prescription benefits. 在开处方时实现价格透明，并提供实时处方福利。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2024-09-23 DOI: 10.1093/ajhp/zxae108

Austin Fitts, Andrew J Teare, Scott D Nelson

{"title":"Price transparency at the point of prescribing with real-time prescription benefits.","authors":"Austin Fitts, Andrew J Teare, Scott D Nelson","doi":"10.1093/ajhp/zxae108","DOIUrl":"10.1093/ajhp/zxae108","url":null,"abstract":"Purpose: Real-time prescription benefits (RTPB) shows prescribers patient-, medication-, and pharmacy-specific information on medication pricing, prior authorization requirements, and lower-cost alternatives. RTPB is intended to improve patient satisfaction and prescription fill rates by decreasing out-of-pocket costs for prescriptions. Therefore, we evaluated how RTPB affects prescribing patterns by examining acceptance and subsequent fill rates for RTPB alternative suggestions.Methods: RTPB was implemented in February 2022 using external vendor interfaces. Prescribing data from March 2022 to March 2023 were analyzed. RTPB displayed alerts for medications requiring prior authorization or when alternative medications would result in cost savings. Patients were included if their prescription received an RTPB response and they had a subsequent encounter with pharmacy fill data. Primary outcomes were alert acceptance rates and prescription fill rates across RTPB alert groups, with a secondary outcome of monthly copay savings for accepted alerts.Results: RTPB requests received a response for 88% of prescriptions, with price estimates provided for 77.9% of them. Lower-cost alternatives accounted for 67.2% of alerts, while prior authorization requirements represented 15% of alerts. Prescribers selected a lower-cost alternative 32% of the time. For those with an RTPB alert, patients filled prescriptions 68% of the time when an alternative was chosen, compared to 59% of the time when the original prescription was retained (odds ratio, 1.5; 95% confidence interval, 1.5-1.6; P < 0.001). Patients saved an average of $27.77 per month on copay costs when alternatives were selected.Conclusion: Implementation of RTPB was found to result in significant improvements in prescription fill rates and decrease patient copay costs, despite low alert acceptance rates.","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140875587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Respiratory Syncytial Virus Vaccine (mRNA). 呼吸道合胞病毒疫苗（mRNA）。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2024-09-23 DOI: 10.1093/ajhp/zxae180

引用次数: 0

Integration of a clinical pharmacist practitioner-led pharmacogenomics service in a Veterans Affairs hematology/oncology clinic. 在退伍军人事务血液学/肿瘤学诊所整合由临床药剂师主导的药物基因组学服务。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2024-09-23 DOI: 10.1093/ajhp/zxae122

Emma Dreischmeier, Hannah Hecht, Edward Crocker, Ellina Seckel, Andrew Wilcox, Christopher Fletcher, Jennifer Piccolo

{"title":"Integration of a clinical pharmacist practitioner-led pharmacogenomics service in a Veterans Affairs hematology/oncology clinic.","authors":"Emma Dreischmeier, Hannah Hecht, Edward Crocker, Ellina Seckel, Andrew Wilcox, Christopher Fletcher, Jennifer Piccolo","doi":"10.1093/ajhp/zxae122","DOIUrl":"10.1093/ajhp/zxae122","url":null,"abstract":"Purpose: This article describes the implementation and evaluation of pharmacogenomic testing within the hematology/oncology ambulatory care clinic at the William S. Middleton Memorial Veterans Hospital in Madison, WI.Summary: The Pharmacogenomic Testing for Veterans (PHASER) program provides preemptive pharmacogenomic testing for veterans nationally. Program implementation at the Madison Veterans Affairs site began in the hematology/oncology clinic with the goal of integrating the offer for pharmacogenomic testing, testing completion, and review of the results by the hematology/oncology clinical pharmacist practitioner (CPP) into current workflows to create a sustainable process for PHASER. The hematology/oncology CPP designed workflows outlining how testing would be offered to patients, how results would be reported and to whom, and how documentation would occur in the electronic medical record. Veterans are offered preemptive PHASER testing, before needing therapy requiring pharmacogenomic results. Exceptions to pharmacogenomic testing were patients with a history of liver or allogeneic hematopoietic stem cell transplantation.Conclusion: This article provides a summary of the role of the hematology/oncology CPP in the implementation of a pharmacogenomics service and the impact on medication management in a hematology/oncology clinic.","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140908310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Interventions to reduce waste and improve billing compliance with medications in single-dose vials. 更正为采取干预措施，减少浪费并提高单剂量小瓶药物的账单合规性。

IF 2.1 4区医学

American Journal of Health-System Pharmacy Pub Date : 2024-09-23 DOI: 10.1093/ajhp/zxae230

引用次数: 0